Next Post

$500m CartiHeal sale to go ahead after FDA approval granted

&#13 US orthologics company Bioventus (Nasdaq: BVS) can now move forward with its $500 million acquisition of CartiHeal, just after the Israeli clinical device company gained Fda clearance for its implants for the procedure of destroyed cartilage. Bioventus signed an settlement to obtain CartiHeal very last July, for $350 million, […]